NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$445.00
Cat.#: 28184 |
Product Name: Anti-VEGFA(DMC276) IgG1 Chimeric Monoclonal Antibody |
Synonyms: MVCD1; VEGF; VPF |
Description: Anti-VEGFA antibody(DMC276) IgG1 Chimeric Monoclonal Antibody |
Background: This gene is a member of the PDGF:VEGF growth factor family. It encodes a heparin-binding protein; which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells; and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome; also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism; and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame; which is located within an internal ribosome entry site. |
Applications: Flow Cyt |
Recommended Dilutions: Flow Cyt 1:100 |
Host Species: Rabbit |
Isotype: Rabbit:Human Fc chimeric IgG1 |
Purification: Purified from cell culture supernatant by affinity chromatography |
Species Reactivity: Human VEGFA |
Constituents: Lyophilized from sterile PBS, pH 7.4. 5 % – 8% trehalose is added as protectants before lyophilization. |
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). |
Figure 1. Flow cytometry analysis with Anti-VEGFA (DMC276) on Expi293 cells transfected with human VEGFA (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram), and Isotype antibody on Expi293 transfected with irrelevant protein (Orange histogram). |